HBIO Stock Forecast 2025-2026
Distance to HBIO Price Targets
HBIO Price Momentum
🤔 Considering Harvard Bioscience (HBIO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest HBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, HBIO has a bullish consensus with a median price target of $4.25 (ranging from $3.00 to $5.50). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.65, the median forecast implies a 556.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HBIO Analyst Ratings
HBIO Price Target Range
Latest HBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 22, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $7.00 |
| Apr 26, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $7.00 |
| Apr 26, 2023 | Benchmark | Bruce Jackson | Buy | Maintains | $7.00 |
| Mar 10, 2023 | Benchmark | Kenneth Bruce | Buy | Reiterates | $4.00 |
| Nov 9, 2022 | Keybanc | Paul Knight | Overweight | Maintains | $5.00 |
| Aug 5, 2022 | Keybanc | Paul Knight | Overweight | Maintains | $7.00 |
| Nov 10, 2020 | Keybanc | Overweight | Initiates | $0.00 | |
| Nov 10, 2020 | KeyBanc | Overweight | Initiates | $0.00 | |
| Feb 27, 2020 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $4.00 |
| Nov 17, 2016 | Singular Research | Buy | Initiates | $0.00 | |
| Jul 28, 2015 | Benchmark | Buy | Initiates | $0.00 | |
| Nov 26, 2013 | Sidoti & Co. | Buy | Upgrade | $0.00 |
Harvard Bioscience Inc. (HBIO) Competitors
The following stocks are similar to Harvard Bioscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Harvard Bioscience Inc. (HBIO) Financial Data
Harvard Bioscience Inc. has a market capitalization of $28.26M with a P/E ratio of -8.1x. The company generates $94.14M in trailing twelve-month revenue with a -13.2% profit margin.
Revenue growth is -12.8% quarter-over-quarter, while maintaining an operating margin of +0.9% and return on equity of -18.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Harvard Bioscience Inc. (HBIO) Business Model
About Harvard Bioscience Inc.
Develops scientific instruments and systems for research.
Harvard Bioscience generates revenue by developing, manufacturing, and distributing a range of scientific instruments and consumables tailored for life science research. The company serves various sectors including biotechnology, pharmaceuticals, and academic institutions, providing essential tools that enhance research capabilities and drive advancements in medical and life sciences.
Headquartered in Holliston, Massachusetts, Harvard Bioscience is committed to evolving its product offerings to meet market demands and support scientific innovation. By addressing the needs of researchers, the company plays a crucial role in the scientific research infrastructure and contributes to advancements that can improve global health outcomes.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
391
CEO
Mr. James W. Green
Country
United States
IPO Year
2001
Website
www.harvardbioscience.comHarvard Bioscience Inc. (HBIO) Latest News & Analysis
Harvard Bioscience, Inc. (NASDAQ: HBIO) will host its Q4 2024 results conference call on March 12, 2025, at 8:00 AM ET, featuring key executives and analysts.
Harvard Bioscience's Q4 results call indicates upcoming financial performance insights, crucial for assessing company health and potential investment opportunities.
Harvard Bioscience, Inc. (Nasdaq: HBIO) announced its financial results for Q4 and the full year ended December 31, 2024, on March 12, 2025.
Harvard Bioscience's financial results can impact stock performance, influencing investor sentiment and potential market valuation based on revenue, profit margins, and future guidance.
Harvard Bioscience, Inc. (Nasdaq: HBIO) executives Jim Green and Jennifer Cote will attend two investor conferences in March 2025.
Participation in investor conferences can indicate company transparency and engagement, potentially influencing investor sentiment and stock performance for Harvard Bioscience.
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET
18 days agoHarvard Bioscience, Inc. (Nasdaq: HBIO) will report Q4 2024 financial results on March 12, 2025, before market open, followed by a conference call at 8:00 a.m. ET.
Harvard Bioscience's upcoming financial results announcement could impact stock performance, revealing insights into company health and future prospects.
Advanced platforms are being developed to boost productivity for Contract Research Organizations (CROs), pharmaceutical, and biotech companies.
Enhanced productivity in CROs and biotech firms can lead to faster drug development and increased revenue, positively impacting stock performance and investor sentiment in the sector.
Harvard Bioscience, Inc. (Nasdaq: HBIO) will present at the Sidoti Micro Cap Virtual Conference on January 22, 2025, at 10:00 am ET, featuring CEO Jim Green and CFO Jennifer Cote.
Harvard Bioscience's participation in a micro-cap conference may indicate efforts to attract investor interest and boost stock visibility, potentially affecting share price and market perception.
Frequently Asked Questions About HBIO Stock
What is Harvard Bioscience Inc.'s (HBIO) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Harvard Bioscience Inc. (HBIO) has a median price target of $4.25. The highest price target is $5.50 and the lowest is $3.00.
Is HBIO stock a good investment in 2025?
According to current analyst ratings, HBIO has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HBIO stock?
Wall Street analysts predict HBIO stock could reach $4.25 in the next 12 months. This represents a 556.0% increase from the current price of $0.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Harvard Bioscience Inc.'s business model?
Harvard Bioscience generates revenue by developing, manufacturing, and distributing a range of scientific instruments and consumables tailored for life science research. The company serves various sectors including biotechnology, pharmaceuticals, and academic institutions, providing essential tools that enhance research capabilities and drive advancements in medical and life sciences.
What is the highest forecasted price for HBIO Harvard Bioscience Inc.?
The highest price target for HBIO is $5.50 from at , which represents a 748.9% increase from the current price of $0.65.
What is the lowest forecasted price for HBIO Harvard Bioscience Inc.?
The lowest price target for HBIO is $3.00 from at , which represents a 363.0% increase from the current price of $0.65.
What is the overall HBIO consensus from analysts for Harvard Bioscience Inc.?
The overall analyst consensus for HBIO is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.25.
How accurate are HBIO stock price projections?
Stock price projections, including those for Harvard Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
